| Thu, 13 May 2021 12:09:42: | NEA-backed Allay exits stealth with clinical pain data, plans to reduce need for opioids
|
| Thu, 13 May 2021 11:33:41: | Autolus' CD19 CAR-T posts 100% complete response rate, zero grade 3 CRS in small lymphoma trial
|
| Thu, 13 May 2021 11:26:23: | How a genetic 'CopyCatcher' could open the door to CRISPR-based precision gene therapy
|
| Wed, 12 May 2021 13:02:58: | Biogen buys midphase drug to challenge Roche for stroke market
|
| Wed, 12 May 2021 12:47:31: | Alexion founder Squinto helms OrbiMed-backed startup with some Yale gene therapy tech
|
| Wed, 12 May 2021 12:12:51: | As data near, U.K. rethinks AstraZeneca COVID-19 antibody deal
|
| Wed, 12 May 2021 09:05:09: | Call for your Fierce Biotech Fierce 15 nominations for 2021
|
| Tue, 11 May 2021 18:00:31: | Amgen, AstraZeneca's tezepelumab is looking for a slice of blockbuster asthma market dominated by Sanofi's Dupixent
|
| Tue, 11 May 2021 11:59:10: | Ginkgo lands on NYSE via $17.5B SPAC merger, giving it billions to fuel growth
|
| Tue, 11 May 2021 08:34:38: | Nuvalent bags $135M to trial resistance-beating kinase inhibitors in lung cancer
|
| Tue, 11 May 2021 06:19:13: | Lilly, MiNA ink broad deal to upregulate proteins using RNA
|
| Mon, 10 May 2021 18:39:17: | COVID-flu combo vaccine from Novavax sparks immune response to both viruses in animals
|
| Mon, 10 May 2021 14:25:36: | Attacking aging and chronic disease by eliminating 'senescent' cells with immunotherapy
|
| Mon, 10 May 2021 12:20:16: | Bayer's near-approval Farxiga rival meets goal in 2nd phase 3
|
| Mon, 10 May 2021 01:02:59: | Flagship debuts Laronde to develop RNA-based meds that could turn cells into protein factories
|
| Fri, 07 May 2021 14:17:38: | Daiichi Sankyo, AstraZeneca's $5B Enhertu follow-up shows early signs of success in breast cancer
|
| Fri, 07 May 2021 13:50:22: | Gene therapy biotech Gyroscope finds unnavigable seas on IPO market
|
| Fri, 07 May 2021 10:49:22: | Adcomm experts split on whether to approve ChemoCentryx's avacopan
|
| Fri, 07 May 2021 10:07:57: | Galapagos cuts pipeline, targets €150M in savings after setbacks
|
| Fri, 07 May 2021 08:15:38: | Science 37 taps a SPAC to go public, with siteless trial specialist valued at a cool $1B
|
| Fri, 07 May 2021 08:02:31: | CRISPR therapeutics, Nkarta pen new cutting-edge cancer tech research pact
|
| Thu, 06 May 2021 21:21:13: | Chutes & Ladders—Former Merck R&D chief Perlmutter takes reins at Eikon, applying Nobel-winning tech to drug discovery
|
| Thu, 06 May 2021 12:49:53: | Merck takes $170M charge on abandoned COVID-19 drug
|
| Thu, 06 May 2021 12:11:08: | Bluebird names oncology spinoff, establishes leadership team
|
| Thu, 06 May 2021 10:08:28: | A cancer vaccine built from stem cells? Stanford candidate shows promise in pancreatic tumors
|
